Cathomen

Center for Chronic Immunodeficiency
Institute for Transfusion Medicine and Gene Therapy
Director
Phone: 0049-761-270-34800
toni.cathomen@uniklinik-freiburg.de
www.uniklinik-freiburg.de/itg-en

1998-2002 Postdoctoral Fellow, Laboratory of Genetics, The Salk Institute, La Jolla, USA
2002-2003 Senior Research Associate, The Salk Institute, La Jolla, USA
2003-2009 Assistant Professor of Molecular Virology, Charité Medical School, Berlin, Germany
2009-2012 Associate Professor of Experimental Hematology, Hannover Medical School, Germany
Since 2012 Full Professor (W3) and Director of the Institute for Cell and Gene Therapy, Medical Center - University of Freiburg

To improve TALEN and CRISPR-Cas platforms for therapeutic applications in human stem cells
To develop disease models and cell therapies based on induced pluripotent stem cells (iPSCs)
To translate into the clinic cell and gene therapies for patients suffering from primary immunodeficiencies, HIV infection or leukemia

Lee SH, ... Cathomen T*, Kim J-S*. Failure to detect DNA-guided genome editing using Natronobacterium gregoryi argonaute (Correspondence). Nat Biotechnol. 2016; 35, 17-18 (*corresponding authors).
Müller M, ... Cathomen T*, Mussolino C*. Streptococcus thermophilus CRISPR-Cas9 systems enable specifi c editing of the human genome. Mol Ther. 2016; 24,636-44. (*corresponding authors).
Dreyer A-K, ... Cathomen T. TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials.2015; 69,191-200.
Rahman SH, ... Cathomen T. Rescue of DNA-PK signaling and T-cell differentiation by targeted genome editing in a prkdc deficient iPSC disease model. PLoS Genet. 2015; 11, e1005239.
Mussolino C, ... Cathomen T. TALENs facilitate targeted genome editing in human cells with high specifi city and low cytotoxicity. Nucleic Acids Res. 2014; 42,6762-73.